Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus

Journal of Infectious Diseases

Volumn 186, Issue 9, 2002, Pages 1366-1370

  Gaud, C ^ba   Contant, M ^ba   Arlet Suau, E ^ax   Thiercelin, M F ^ax   Yeni, P ^j   Mandet, C ^j   Bouvet, E ^j   Gaudebout, C ^j   Crickx, B ^j   Picard Dahan, C ^j  

^a Hopital Bonnet   (France)

^b Hop l'Archet Rte S Antoine G   (France)

^c D Hématologie   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e INSERM   (France)

^f Hôpital Cochin ^*  (France)

^g HÔPITAL SAINTE MARGUERITE   (France)

^h French Ministry of Health   (France)

ⁱ Statistical Data Analysis Center   (United States)

^j BICHAT HOSPITAL   (France)

^k HÔPITAL BROUSSAIS   (France)

^l GH Tarnier Cochin ^*  (France)

^m HÔPITAL SAINT JOSEPH   (France)

ⁿ Hôpital Necker adultes   (France)

^o Hopital Laennec   (France)

^p HÔPITAL ANTOINE BÉCLÈRE   (France)

^q BICÊTRE HOSPITAL   (France)

^r HENRI MONDOR HOSPITAL   (France)

^s HÔPITAL ROTHSCHILD   (France)

^t HÔPITAL SAINT ANTOINE   (France)

^u HÔPITAL TENON   (France)

^v PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^w SAINT LOUIS HOSPITAL   (France)

^x GH Lariboisière Fernand Widal   (France)

^y HÔPITAL AMBROISE PARÉ   (France)

^z HÔPITAL LOUIS MOURIER   (France)

^aa RAYMOND POINCARÉ HOSPITAL   (France)

^ab AVICENNE HOSPITAL   (France)

^ac Jean Verdier   (France)

^ad DELAFONTAINE HOSPITAL   (France)

^ae UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^af UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^ag UNIVERSITY HOSPITAL OF BESANÇON   (France)

^ah GRENOBLE UNIVERSITY HOSPITAL   (France)

^ai CROIX ROUSSE HOSPITAL   (France)

^aj EDOUARD HERRIOT HOSPITAL   (France)

^ak HÔTEL DIEU   (France)

^al HÔPITAL DE LA CONCEPTION   (France)

^am Hopital Felix Houphouet Boigny   (France)

^an INSTITUT PAOLI CALMETTES   (France)

^ao Centre p nitentiaire des Baumettes   (France)

^ap CH de Gap   (France)

^aq CHI de Toulon   (France)

^ar MONTPELLIER UNIVERSITY HOSPITAL   (France)

^as CHU NANCY BRABOIS   (France)

^at NANTES UNIVERSITY HOSPITAL   (France)

^au RENNES UNIVERSITY HOSPITAL   (France)

^av ROUEN UNIVERSITY HOSPITAL   (France)

^aw UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^ax CHU PURPAN   (France)

^ay UNIVERSITY HOSPITAL OF TOURS   (France)

^az CISIH outside France   (France)

^ba CISIH de Martinique (CHRU de Fort de France)   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG USE; FEMALE; FOLLOW UP; FRANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LEISHMANIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PARASITE CULTIVATION; PRIORITY JOURNAL; RISK FACTOR; VISCERAL LEISHMANIASIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; FRANCE; GEOGRAPHY; HIV INFECTIONS; HUMANS; INCIDENCE; LEISHMANIASIS, VISCERAL; MALE; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS;

EID: 0036839245     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/344325     Document Type: Article

References (16)

1. Alvar J, Cañavate C, Gutierrez-Solar B, et al. Leishmania and human immunodeficiency virus co-infection: The first 10 years. Clin Microbiol Rev 1997; 10:298-319.
2. Munoz A, Sabin CA, Phillips AN. The incubation period of AIDS. AIDS 1997; 11 (Suppl A):S69-76.
3. Glesby MJ, Hoover DR. Survivor treatment selection bias in observational studies: Examples from the AIDS literature. Ann Intern Med 1996; 124: 999-1005.
4. Tumbarello M, Tacconelli E, Bertagnolio S, Cauda R. Highly active antiretroviral therapy decreases the incidence of visceral leishmaniasis. AIDS 2000; 14:2948-50.
5. Tortajada C, Perez-Cuevas JB, Moreno A, et al. Declining incidence and better outcome of visceral leishmaniasis in the era of HAART [poster 550]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 2001.
6. Rosenthal E, Tempesta S, Del Giudice P, et al. Incidence of visceral leishmaniasis in HIV-infected individuals in southern France in the era of highly active antiretroviral therapy. AIDS 2001;15:1184-5.
7. Lopez-Velez R, Casado JL, Pintado V. Decline of visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly antiretroviral therapy. Clin Microbiol Infect 2001; 7:394-5.
8. De La Rosa R, Pineda JA, Delgado J, et al. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency-infected patients. Clin Infect Dis 2001;32:633-5.
9. Villanueva JL, Alarcon A, Bernabeu-Wittel M, et al. Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2000 19:798-801.
10. Mastroianni CM, D'Ettorre G, Forcina G, et al. Long-term remission of human immunodeficiency virus-associated visceral leishmaniasis after initiation of potent combination antiretroviral treatment: Report of two cases. J Infect 2000; 40:94-6.
11. Petter A, Shetty-Lee A, Kofler G, Huemer HP, Larcher C. Visceral leishmaniasis in an AIDS patient on successful antiretroviral therapy: failure of parasite eradication despite increase in CD4 T-cell count but low CD8 T-cell count. Scand J Infect Dis 2001;33:236-8.
12. Berenguer J, Cosin, Miralles P, Lopez JC, Padilla B. Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS 2000; 14:2946-7.
13. Casado JL, Lopez-Velez R, Pintado V, Querada C, Antela A, Moreno S. Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. Eur J Clin Microbiol Infect Dis 2001;20:202-5.
14. Jimenez-Exposito MJ, Alonso-Villaverde C, Sarda P, Masana L. Visceral leishmaniasis in HIV-infected patients with non-detectable HIV-1 viral load after highly active antiretroviral therapy. AIDS 1999;13:152-3.
15. Derouin F, Santillana-Hayat M. Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro. Antimicrob Agents Chemother 2000;44:2575-7.
16. Cruz I, Morales MA, Noguer A, Rodriguez, Alvar J. Leishmania in discarded syringes from intravenous drug users. Lancet 2002;359:1124-5.